_Meet our ongoing investments

Our mission is simple – provide our investors with access to the most promising and impactful life sciences technologies.

We focus mostly on early-stage companies developing novel therapies in Europe and the US. Within therapeutics, we remain agnostic in terms of indication and modality, but value highly differentiated companies targeting clear unmet needs.

 
Doctify
Healthcare review platform
UK
Eveliqure
First shigella and ETEC vaccine
Austria
Calyxha
Targeting tissue degeneration
Austria
Cebina
Life sciences Accelerator
Austria
Spiral
Hearing loss therapies
USA
Accure
New drugs for CNS disorders
Spain
Aleva
Deep Brain Stimulation therapies
Switzerland